International Journal of Neuropsychopharmacology最新文献

{"title":"Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences.","authors":"Cheng Jiang, Luhan Tang, Mingqian Li, Guoqin Xia","doi":"10.1093/ijnp/pyag022","DOIUrl":"10.1093/ijnp/pyag022","url":null,"abstract":"<p><strong>Background: </strong>Lumateperone, a novel atypical antipsychotic, has emerged as an illuminating hope for patients with schizophrenia and bipolar disorder. While prior studies have employed spontaneous reporting databases and identified over 100 novel adverse events associated with lumateperone, the differences in these adverse events across subgroups remain unclear.</p><p><strong>Objective: </strong>This study provides a comprehensive evaluation of the adverse event profile of lumateperone using the Food and Drug Administration Adverse Event Reporting System database, focusing on the potential differences in reporting adverse events across subgroups.</p><p><strong>Methods: </strong>Based on the results of clinical characteristics and signal detection, the potential differences in reporting lumateperone-associated adverse events across specific subgroups regarding report year, reporter type, sex, age, outcome, indication, and concomitant drug were analyzed using the reporting odds ratio algorithm and Fisher's exact test with Bonferroni correction. The observed differences were further validated using sensitivity analyses, stratified analyses, and comparative analyses.</p><p><strong>Results: </strong>This study identified 1762 reports and 5074 adverse events associated with lumateperone. Notably, females had a higher frequency of reporting nervous system disorders. Tardive dyskinesia was more frequently resulted in serious consequences. Moreover, bipolar disorder patients more frequently reported nervous system disorders, while schizophrenia patients more frequently reported psychiatric disorders.</p><p><strong>Conclusions: </strong>This study underscores the need for future confirmatory studies into the potential sex, outcome and indication differences in adverse events associated with lumateperone. The findings should be considered preliminary and require further validation.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-onset major depression and subthreshold depressive symptoms as early clinical correlates of brain small vessel disease.","authors":"Calypso A Mitkani, Thomas J Tegos, Vasilios K Kimiskidis, Stavroula Koukou, Konstantinos N Fountoulakis","doi":"10.1093/ijnp/pyag024","DOIUrl":"10.1093/ijnp/pyag024","url":null,"abstract":"<p><p>Late-onset depression (LOD) and subthreshold depressive symptoms (SDS) have been associated with cerebral small vessel disease (SVD), but the evidence regarding pre-stroke depression remains limited. This study examined the frequency of DSM-5 LOD and SDS prior to the first non-embolic lacunar stroke. Fifty-eight patients (mean age 62.2 ± 8.2 years; 41.4% female) with a first lacunar ischemic stroke underwent Magnetic Resonance Imaging (MRI) (T1, T2, FLAIR sequences) and psychiatric evaluation using the MINI, with data from caregivers and medical records. Patients were classified as having LOD (D), SDS (S), combined (S/D), or none (nD/S). Statistical analyses included Mann-Whitney U and Fisher's Exact tests. Of the total sample, 63.8% (n = 37) exhibited LOD or SDS, with reported onset on average 5-7 years prior to stroke (mean onset age: 55.5 years). Females exhibited higher prevalence of depressive symptoms (87.5% vs 47.1%, P = .001). Hypertension (75.7%) and dyslipidemia (62.2%) were the most common vascular risk factors. No patient had manic or hypomanic episodes. Premorbid depressive symptoms were common and may precede the clinical manifestation of cerebrovascular disease Given the retrospective and observational design, these findings should be regarded as hypothesis-generating rather than causal. Prospective longitudinal studies incorporating quantitative SVD imaging markers are required.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13196579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of adjunctive brexpiprazole with selective serotonin reuptake inhibitor treatment on anxiety and sleep architecture in mice.","authors":"Junya Maruoka, Kohei Kozuka, Ryo Egami, Yusuke Kubo, Yusuke Kakumoto, Tetsuro Kikuchi, Kazuhiko Kume","doi":"10.1093/ijnp/pyag007","DOIUrl":"10.1093/ijnp/pyag007","url":null,"abstract":"<p><strong>Introduction: </strong>Major depressive disorder (MDD) is frequently accompanied by residual symptoms such as anxiety and sleep disturbances, even after adequate antidepressant treatment. Brexpiprazole, a serotonin-dopamine activity modulator, has shown efficacy as adjunctive therapy for MDD. However, its mechanistic contribution to anxiety and sleep regulation remains unclear. This study aimed to evaluate the combined effects of brexpiprazole and paroxetine, a selective serotonin reuptake inhibitor (SSRI), on anxiety-like behavior and sleep architecture in mice.</p><p><strong>Methods: </strong>We used male Crl:CD1 and C57BL/6J mice. Anxiety-like behavior was assessed using the marble-burying behavior (MBB) test using Crl:CD1 mice. We also evaluated locomotor activity (LA) monitored to exclude sedative effects. Sleep architecture was evaluated via cortical electroencephalography and electromyography, quantifying Wake, rapid eye movement (REM) sleep, and non-REM (NREM) sleep stages using C57BL/6J mice.</p><p><strong>Results: </strong>In MBB test, paroxetine reduced buried marbles without affecting LA, whereas brexpiprazole alone was ineffective. The combination of brexpiprazole (0.1 mg/kg) and paroxetine (0.75 mg/kg) significantly decreased buried marbles. Next, to explore the role of α2C adrenoreceptor (AR) antagonism, JP-1302 (a selective α2C AR antagonist) was also tested. Similarly, JP-1302 (30 mg/kg) combined with paroxetine (0.75 mg/kg) decreased buried marbles. In sleep architecture, brexpiprazole dose-dependently decreased Wake and increased NREM sleep, while paroxetine primarily reduced REM sleep. Combined administration decreased Wake and REM sleep and increased NREM sleep. The combination showed effects comparable to each drug administered alone.</p><p><strong>Conclusions: </strong>In this study, we demonstrated that the combination of brexpiprazole and paroxetine produced anxiolytic-like effects and altered sleep architecture in mice. Furthermore, the anxiolytic-like effect of the combination suggests that brexpiprazole's α2C AR antagonistic activity may be one of several plausible contributors. Adjunctive brexpiprazole may influence anxiety and sleep architecture, potentially contributing to the management of residual symptoms in MDD.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying treatment response classes to transcranial direct current stimulation from daily ecological momentary assessment patterns in patients with depression.","authors":"Han Wool Jung, Sehwan Park, Kyungmi Chung, Yujin Kim, Daeyoung Roh, Kyungun Jhung, Woo Jung Kim, Jin Young Park, Jaesub Park","doi":"10.1093/ijnp/pyag012","DOIUrl":"10.1093/ijnp/pyag012","url":null,"abstract":"<p><strong>Importance: </strong>Transcranial direct current stimulation (tDCS) is known to be promising for depression, but heterogeneity across studies highlights the need for strategies to optimize treatment effectiveness. Identifying distinct response patterns based on ecological momentary assessment (EMA) may enhance therapeutic outcomes and support the development of personalized and precision psychiatry.</p><p><strong>Objective: </strong>To identify distinct EMA-derived response profiles to tDCS in patients with depression and examine how the identified subtypes differentially predict treatment responses and symptom return following treatment termination.</p><p><strong>Design: </strong>A secondary analysis of a double-blind, multicenter randomized clinical trial investigating the effects of tDCS on depression. Daily EMA data on mood and sleep duration during the intervention period were processed using time-series feature extraction and clustered via Gaussian Mixture Modeling.</p><p><strong>Participants: </strong>One hundred and ninety-seven participants (original study) and 147 participants (current study) diagnosed with mild-to-moderate depression.</p><p><strong>Interventions or exposures: </strong>Six-week active tDCS vs 3-week active and 3-week sham tDCS.</p><p><strong>Main outcomes and measures: </strong>Beck Depression Inventory-II (BDI-II) and Montgomery-Åsberg Depression Rating Scale (MADRS) measured at baseline (V1), post-treatment (V3), and 6-week follow-up (V4).</p><p><strong>Results: </strong>Clustering analysis identified 3 response types: (1) stable improvement (gradual mood reduction, stable sleep duration, moderate treatment effect with no symptom return), (2) persistent high-symptom (consistently elevated depressive mood, sleep disturbance, low-to-moderate treatment effect without symptom return), and (3) volatile symptom (large day-to-day variability in mood and sleep, marked acute improvement but high symptom return). The linear mixed model identified significant interaction effects between clusters and treatment efficacy (V1, V3)/symptom return (V3, V4) intervals.</p><p><strong>Conclusions and relevance: </strong>Clustering of daily EMA data identified 3 distinct tDCS response profiles associated with different clinical characteristics and relapse risks. These patterns may reflect underlying subtypes of depression and highlight the value of individualized treatment planning. Future studies can fully characterize the subtypes of response profiles and the unique response patterns of individuals that may facilitate data-driven decision-making and support precision psychiatry by enabling tailored tDCS protocols based on patient-specific response characteristics.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-density EEG study in patients with schizophrenia treated with cariprazine.","authors":"Pál Czobor, Brigitta Kakuszi, Máté Fullajtár, István Bitter","doi":"10.1093/ijnp/pyag008","DOIUrl":"10.1093/ijnp/pyag008","url":null,"abstract":"<p><strong>Background: </strong>Schizophrenia is marked by persistent negative and cognitive symptoms that remain difficult to treat. Cariprazine, a dopamine D3/D2 partial agonist, has demonstrated efficacy in these domains, making it essential to clarify its neurophysiological mechanisms both for future drug discovery and clinical application. Resting-state EEG spectral analysis provides a non-invasive and translational tool for monitoring neurophysiological changes related to treatment. However, data on EEG spectral effects in human patients treated with cariprazine are currently lacking.</p><p><strong>Methods: </strong>In this open-label investigation, 27 patients with schizophrenia underwent high-density resting-state EEG before and during cariprazine treatment. Power spectral analyses were conducted across frequency bands and cortical regions, with ROI analyses targeting gamma-activity in DLPFC, IFG, and TPJ. Symptom changes were measured using the Positive and Negative Syndrome Scale.</p><p><strong>Results: </strong>Cariprazine treatment led to symptom improvement, particularly in negative and general domains. EEG analyses showed increased spectral power, most prominently in the theta and alpha bands, mirroring findings from the only available in vivo preclinical study, which also reported theta and alpha elevations in rodents. Symptom reduction was specifically associated with increased theta and decreased delta power. Moreover, baseline gamma-activity-especially in the IFG and DLPFC-predicted treatment response, with Receiver Operating Characteristic analyses yielding AUC values of 0.72-0.92 and cross-validated classification accuracies exceeding 70%.</p><p><strong>Conclusions: </strong>Together, our results demonstrate that resting-state EEG spectral measures reflect neurophysiological correlates of cariprazine response. Furthermore, the findings reinforce the cross-species translatability of spectral measures and support EEG biomarkers as promising translational tools for predicting and monitoring treatment outcomes in schizophrenia.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of nicotinic receptor antagonism on nicotine and THC self-administration in a model of polysubstance use.","authors":"Mary M Torregrossa, Tamara Racic, Samantha L Baglot, Sierra J Stringfield, Matthew N Hill, Alan Sved","doi":"10.1093/ijnp/pyag015","DOIUrl":"10.1093/ijnp/pyag015","url":null,"abstract":"<p><strong>Background: </strong>Most substance users are polysubstance users; however, little is known about how the combined use of different drugs affects the course of substance use disorder or effectiveness of treatment. Notably, co-use of cannabis and nicotine is very common, and we previously demonstrated that nicotine enhances the self-administration of a synthetic cannabinoid receptor agonist and the primary psychoactive phytocannabinoid in cannabis, Δ-9-tetrahydrocannabinol (THC).</p><p><strong>Methods: </strong>Here we aimed to further investigate the patterns of nicotine and THC self-administration when available in a concurrent choice model, and to determine the effects of nicotinic acetylcholine receptor (nAchR) antagonists on nicotine-enhanced THC self-administration in male and female rats.</p><p><strong>Results: </strong>During concurrent choice, nicotine availability increased THC self-administration in females without affecting THC metabolism, while THC availability decreased nicotine self-administration and preference in females relative to when nicotine and saline were concurrently available. In females, THC self-administration was reduced by the α4β2/4 subunit-containing nAchR antagonist dihydro-beta-erythroidine in both nicotine and saline concurrent availability groups; while nicotine self-administration was reduced in both sexes by the α7nAchR antagonist methylylcaconitine, but only in rats that had concurrent access to THC. The nonspecific nAchR antagonist mecamylamine had minimal effects in the concurrent choice model, but it prevented nicotine-induced enhancement of THC self-administration when nicotine was given prior to a single choice THC only self-administration session.</p><p><strong>Conclusions: </strong>Thus, behavioral regulation of self-administration is differentially influenced by nAchR subtypes depending on the availability of other substances, which has implications for the efficacy of treatments in the context of polysubstance use. Significance statement Polysubstance use is extremely common, but very understudied in both clinical and preclinical research. The results presented here highlight that pharmacological modulators of drug reinforcement can differ when multiple drugs are available simultaneously, highlighting the importance of investigating potential treatments for substance use disorders in the context of polysubstance use.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13127143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychostimulant effects on motor and cognitive function in adults attention deficit hyperactivity disorder.","authors":"Maurizio Cundari, Lukas Kanold, David Bergwall, Susanna Vestberg, Amelia Hansson, Lena Kirchhoff, Peik Gustafsson, Anders Rasmussen","doi":"10.1093/ijnp/pyag013","DOIUrl":"10.1093/ijnp/pyag013","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to compare the performance on motor and cognitive functions of adult patients with attention deficit hyperactivity disorder (ADHD) with or without psychostimulant medication and controls. A secondary objective is to investigate differences on test performance across varying levels of disorder severity.</p><p><strong>Methods: </strong>We included patients with unmedicated ADHD (U-ADHD) (n = 52), patients with ADHD treated with psychostimulants (n = 40), and controls (n = 80). A multimodal set of motor and cognitive tests was administered to evaluate cerebellar and motor functions, attention and processing speed, executive functions, visuospatial perception, and visuospatial abilities.</p><p><strong>Results: </strong>Both patient groups performed significantly worse than controls across all functions. No significant performance differences were observed between the medicated and U-ADHD groups when disorder severity was not considered. However, some differences emerged when stratified by disorder severity. Patients with moderate to severe U-ADHD showed more impairments in sensorimotor functions compared to the medicated ADHD (M-ADHD), while those with mild U-ADHD displayed lower scores on visuospatial perception compared to M-ADHD. Regression analysis indicated that education, anxiety, and sleep disturbances minimally affect test performance.</p><p><strong>Conclusions: </strong>In summary, psychostimulant medication did not show consistent overall differences in motor and cognitive performance among adults with ADHD. Importantly, when stratifying by disorder severity, some group-level differences emerged, underscoring the need to account for disorder severity in future research and clinical assessment.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13130065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Exploring the association between sweet liking and treatment response to naltrexone in patients with alcohol use disorder.","authors":"","doi":"10.1093/ijnp/pyag017","DOIUrl":"10.1093/ijnp/pyag017","url":null,"abstract":"","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":"29 4","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study.","authors":"Christine Pinter, Michael E Thase, Roger S McIntyre, Kimberly Cooper, Haiyan Xu, Gahan Pandina, Adam Savitz, Wayne C Drevets","doi":"10.1093/ijnp/pyag009","DOIUrl":"10.1093/ijnp/pyag009","url":null,"abstract":"<p><strong>Importance: </strong>Seltorexant, a selective orexin-2 receptor (OX2R) antagonist, has demonstrated antidepressant effects in major depressive disorder (MDD), particularly among patients with higher baseline insomnia symptoms.</p><p><strong>Objective: </strong>To investigate flexibly dosed seltorexant vs flexibly dosed quetiapine extended release (quetiapine-XR) as adjunctive treatment to a selective serotonin (SSRI) or serotonin-norepinephrine (SNRI) reuptake inhibitor.</p><p><strong>Setting: </strong>Outpatient.</p><p><strong>Design: </strong>Randomized, active-controlled, multicenter, exploratory phase 2 study with screening (≤4 weeks), double-blind treatment (24 weeks), and post-treatment follow-up (2 weeks) phases.</p><p><strong>Participants: </strong>Patients with MDD and inadequate response to 1-3 SSRIs/SNRIs, including an ongoing SSRI/SNRI, in the current depressive episode.</p><p><strong>Interventions: </strong>Flexibly dosed seltorexant (20 or 40 mg) or quetiapine-XR (150 or 300 mg, with 2-day initial dosing of 50 mg) once daily as adjunctive therapy to an SSRI/SNRI. Randomization (1:1) was stratified by baseline Insomnia Severity Index total score (≥15 vs <15). Safety, tolerability, and preliminary efficacy were evaluated.</p><p><strong>Main outcomes and measures: </strong>Primary efficacy endpoint was time to all-cause study drug discontinuation. Secondary efficacy endpoints included change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Subgroup analyses included MADRS change by mode dose (MD; most frequent daily dose received by a patient during the study). Safety and tolerability also were assessed.</p><p><strong>Results: </strong>Time to all-cause discontinuation (estimated 25th percentile [80% CI]: seltorexant, 62 [38, 83] days vs quetiapine-XR, 42 [35, 61] days; hazard ratio [80% CI]: 0.83 [0.6, 1.2]) and all-cause discontinuation (seltorexant, 41.2% vs quetiapine-XR, 47.1%; 2-sided P = .5355) did not differ significantly between treatment groups. For the seltorexant 20-mg MD group, MADRS total scores consistently improved over time and reductions were numerically greater at weeks 18 and 24 versus the seltorexant 40-mg MD and the combined quetiapine-XR groups, and patients with higher baseline insomnia symptoms had greater improvement in MADRS total score, consistent with prior studies showing efficacy at 20 but not 40 mg. Treatment-emergent adverse event rates were 65.4% for seltorexant and 80.8% for quetiapine-XR.</p><p><strong>Conclusions and relevance: </strong>Results support the favorable tolerability and preliminary efficacy of seltorexant 20 mg daily as adjunctive treatment in patients with MDD, especially those with insomnia symptoms, and suggest potential approaches to differentiate seltorexant from quetiapine-XR in future adequately powered studies.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov  identifier: NCT03321526.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional analyses do not implicate opioid signaling in the antidepressant effects of ketamine.","authors":"Gihyun Yoon, Brian Pittman, John H Krystal","doi":"10.1093/ijnp/pyag011","DOIUrl":"10.1093/ijnp/pyag011","url":null,"abstract":"","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}